Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Accenture
Farmers Insurance
US Department of Justice
Cantor Fitzgerald
Merck
Healthtrust
Citi
Chubb

Generated: January 18, 2018

DrugPatentWatch Database Preview

Valeant Pharms Llc Company Profile

« Back to Dashboard

Summary for Valeant Pharms Llc
International Patents:367
US Patents:2
Tradenames:6
Ingredients:6
NDAs:7

Drugs and US Patents for Valeant Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc LIBRIUM chlordiazepoxide hydrochloride INJECTABLE;INJECTION 012301-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MESTINON pyridostigmine bromide TABLET;ORAL 009829-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MESTINON pyridostigmine bromide TABLET, EXTENDED RELEASE;ORAL 011665-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms Llc CAPITAL AND CODEINE acetaminophen; codeine phosphate SUSPENSION;ORAL 086024-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc LIBRIUM chlordiazepoxide hydrochloride INJECTABLE;INJECTION 012301-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-001 Jan 29, 1998 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ➤ Subscribe ➤ Subscribe
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Valeant Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,933,116 Nucleic acid ligand binding site identification ➤ Subscribe
6,762,290 High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors ➤ Subscribe
5,849,479 High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) ➤ Subscribe
6,001,988 High affinity nucleic acid ligands to lectins ➤ Subscribe
5,861,254 Flow cell SELEX ➤ Subscribe
6,300,074 Systematic evolution of ligands by exponential enrichment: Chemi-SELEX ➤ Subscribe
7,005,260 Tenascin-C nucleic acid ligands ➤ Subscribe
6,183,967 Nucleic acid ligand inhibitors to DNA polymerases ➤ Subscribe
5,688,935 Nucleic acid ligands of tissue target ➤ Subscribe
6,229,002 Platelet derived growth factor (PDGF) nucleic acid ligand complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Pharms Llc Drugs

Supplementary Protection Certificates for Valeant Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041 Netherlands ➤ Subscribe PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
C/GB99/043 United Kingdom ➤ Subscribe PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
2006004 Lithuania ➤ Subscribe PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
C/GB06/021 United Kingdom ➤ Subscribe PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
20/2006 Austria ➤ Subscribe PRODUCT NAME: PEGAPTANIB UND SALZE DAVON
2006 00021 Denmark ➤ Subscribe
252 Luxembourg ➤ Subscribe 91252, EXPIRES: 20210131
00C/001 Belgium ➤ Subscribe PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0957929/01 Switzerland ➤ Subscribe PRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
C0013 Belgium ➤ Subscribe PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cipla
Healthtrust
Fish and Richardson
Chubb
Fuji
Citi
Deloitte
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot